EtiraRx
PrivateLast Round
Accelerator
Apr 14, 2026
Total Funding Raised
$3.42M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
EtiraRx operates in Healthcare & Life Sciences and is based in Dallas, Texas. Its latest recorded funding round was an Accelerator round in April 2026.
EtiraRx is a biopharmaceutical company that develops novel cancer therapeutics to treat cancers by validating molecular drivers and evaluating mechanisms of therapy resistance.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EtiraRx Comparables
Compare EtiraRx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Bold Therapeutics Inc. | 80% | |
| HiberCell | 79% | |
| MicroQuin | 78% |
For institutional investors. Book with your work email.
EtiraRx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Apr 14, 2026 | ||||
| Seed | Jun 6, 2025 | ||||
| Seed | Oct 4, 2023 | ||||
| Grant | Aug 15, 2021 |
For institutional investors. Book with your work email.
EtiraRx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| MassChallenge Israel | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 14, 2026
Received funding from MassChallenge.
- Nov 18, 2025
Founder spoke at the Health Cell State of the Industry event.
For institutional investors. Book with your work email.
EtiraRx Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about EtiraRx's valuation, stock price, and market status.
Is EtiraRx a public or private company?
EtiraRx is a private company.
What is the current stock price of EtiraRx?
EtiraRx is a private company, so its shares have no public market price. Caplight tracks EtiraRx's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is EtiraRx worth (valuation)?
Valuation information for EtiraRx is not publicly available.
Can I buy EtiraRx stock?
EtiraRx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was EtiraRx's last funding round?
EtiraRx's most recent funding round was Accelerator on April 14, 2026.
Who are the main investors in EtiraRx?
Key investors in EtiraRx include National Cancer Institute, MassChallenge Israel.
Will EtiraRx IPO soon?
No public IPO plans have been announced for EtiraRx.
How can I track EtiraRx secondary market activity?
Caplight tracks bids, offers, and trades in EtiraRx's shares on secondary markets.